Evidence-based dermatology: number needed to treat and its relation to other risk measures
- PMID: 17367615
- DOI: 10.1016/j.jaad.2006.08.024
Evidence-based dermatology: number needed to treat and its relation to other risk measures
Abstract
When discussing treatment options with patients, clinicians often use terms such as "frequently" or "rarely" when referring to potential benefits or possible harms. Quantitative measurements of treatment benefits and harms derived from randomized clinical trials or meta-analysis such as odds ratios or risk reduction are more precise terms, yet physicians and their patients find them difficult to understand and they are not, therefore, commonly used in clinical practice. To overcome the lack of intuitiveness for traditional measures of risk estimates derived from clinical trials, the number needed to treat (NNT) has been widely recommended as a measure of effectiveness, and number needed to harm as a way of describing risk of possible adverse events. NNT is simply the number of patients who, on average, would need to be treated with a proposed intervention to demonstrate one additional gain over the standard comparator intervention. NNT is an absolute measure and it is calculated as the inverse of the absolute risk reduction. In this article we describe the usefulness and limits of the NNT with particular reference to dermatology, and compare NNT with other relative measures such as the relative risk and relative risk reduction.
Comment in
-
Reporting of number needed to treat and its difficulties.J Am Acad Dermatol. 2007 Oct;57(4):729-30. doi: 10.1016/j.jaad.2007.06.035. J Am Acad Dermatol. 2007. PMID: 17870441 No abstract available.
Similar articles
-
[Number needed to treat: a useful tool for estimating the effectiveness of a treatment].Tijdschr Psychiatr. 2008;50(6):337-43. Tijdschr Psychiatr. 2008. PMID: 18548411 Review. Dutch.
-
Interpretation of absolute measures of disease risk in comparative research.Fam Med. 2007 Jun;39(6):432-5. Fam Med. 2007. PMID: 17549653
-
Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions.J Clin Epidemiol. 2006 Mar;59(3):217-23. doi: 10.1016/j.jclinepi.2005.07.006. Epub 2005 Oct 13. J Clin Epidemiol. 2006. PMID: 16488351 Review.
-
Bias of estimates of the number needed to treat.Stat Med. 2005 Jun 30;24(12):1837-48. doi: 10.1002/sim.2076. Stat Med. 2005. PMID: 15806616
-
[Using "number needed to treat" to interpret treatment effect].Acta Neurol Taiwan. 2006 Jun;15(2):120-6. Acta Neurol Taiwan. 2006. PMID: 16871900 Chinese.
Cited by
-
A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis.Acta Derm Venereol. 2020 Jun 9;100(12):adv00165. doi: 10.2340/00015555-3515. Acta Derm Venereol. 2020. PMID: 32419031 Free PMC article. Review.
-
Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain.Pharmacoecon Open. 2024 Mar;8(2):291-302. doi: 10.1007/s41669-023-00459-2. Epub 2024 Jan 18. Pharmacoecon Open. 2024. PMID: 38236526 Free PMC article.
-
Understanding and Evaluating Systematic Reviews and Meta-analyses.Indian J Dermatol. 2014 Mar;59(2):134-9. doi: 10.4103/0019-5154.127671. Indian J Dermatol. 2014. PMID: 24700930 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical